Literature DB >> 8540690

Use of amphotericin B with azole antifungal drugs: what are we doing?

A M Sugar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8540690      PMCID： PMC162855          DOI： 10.1128/AAC.39.9.1907

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  38 in total

1.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

Authors:  S Redding; J Smith; G Farinacci; M Rinaldi; A Fothergill; J Rhine-Chalberg; M Pfaller
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

2.  Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients.

Authors:  A Vuffray; C Durussel; P Boerlin; F Boerlin-Petzold; J Bille; M P Glauser; J P Chave
Journal:  AIDS       Date:  1994-05       Impact factor: 4.177

3.  Correlation between in vitro and in vivo activity of antifungal agents against Candida species.

Authors:  E J Anaissie; N C Karyotakis; R Hachem; M C Dignani; J H Rex; V Paetznick
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

4.  Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients.

Authors:  N Troillet; C Durussel; J Bille; M P Glauser; J P Chave
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

5.  Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B.

Authors:  A M Sugar; M Salibian; L Z Goldani
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

6.  The interaction of miconazole and ketoconazole with lipids.

Authors:  H Van den Bossche; J M Ruysschaert; F Defrise-Quertain; G Willemsens; F Cornelissen; P Marichal; W Cools; J Van Cutsem
Journal:  Biochem Pharmacol       Date:  1982-08-15       Impact factor: 5.858

Review 7.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

8.  Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum.

Authors:  E Martin; F Maier; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism.

Authors:  A Schaffner; A Böhler
Journal:  Mycoses       Date:  1993 Nov-Dec       Impact factor: 4.377

10.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245
View more
  27 in total

Review 1.  Fungal resistance.

Authors:  H Bernhardt; K Zimmermann; M Knoke
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  Challenges in designing animal studies to detect antagonism of polyene activity.

Authors:  Russell E Lewis; Dimitrios P Kontoyiannis; Dimitrios P Kantoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy.

Authors:  D P Kontoyiannis; R E Lewis; N Sagar; G May; R A Prince; K V Rolston
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 5.  Key issues concerning fungistatic versus fungicidal drugs.

Authors:  J R Graybill; D S Burgess; T C Hardin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 6.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

7.  Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; L K Najvar; R Bocanegra; F Caselli; S Di Cesare; D Giannini; L F Di Francesco; A Giacometti; F Carle; G Scalise; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

8.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.

Authors:  R E Lewis; B C Lund; M E Klepser; E J Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 10.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.